Impact of early viral kinetics on pegylated interferon alpha 2b plus ribavirin therapy in Japanese patients with genotype 2 chronic hepatitis C

Journal of Viral Hepatitis

Volumn 16, Issue 5, 2009, Pages 346-351

  Nomura, Hideyuki ^a   Miyagi, Y ^a   Tanimoto, H ^a   Ishibashi, H ^b  

^a Shin Kokura Hospital   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

Author keywords

Chronic hepatitis C; Early viral kinetics; Genotype 2; Pegylated interferon plus ribavirin; Rebound index

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; JAPANESE; KINETICS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 63549139100     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01099.x     Document Type: Article

References (23)

1. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 965.
2. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 982.
3. Tsubota A, Chayama K, Ikeda K et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994 19 : 1088 1094.
4. Reichard O, Glaumann H, Fryden A et al. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology 1995 21 : 918 922.
5. Shiratori Y, Kato N, Yokosuka O et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology 1997 113 : 558 566.
6. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003 362 : 2095 2100.
7. Dai CY, Chuang WL, Chang WY et al. Tumor necrosis factor-alpha promoter polymorphism at position-308 predicts response to combination therapy in hepatitis C virus infection. J Infect Dis 2006 193 : 98 101.
8. Nomura H, Kimura Y, Tada H et al. Predictive factors of a response to interferon therapy in chronic hepatitis C. J Clin Gastroenterol 1996 23 : 185 190.
9. Zeuzem S, Hultcrantz R, Bourliere M et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004 40 : 993 999.
10. Hadziyannis SJ, Sette Jr. H, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 : 346 355.
11. Strader DB, Wright T, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004 39 : 1147 1171.
12. Mangia A, Santoro R, Minerva N et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005 352 : 2609 2617.
13. Dalgard O, Bjoro K, Hellum KB et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004 40 : 1260 1265.
14. von Wagner M, Huber M, Berg T et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005 129 : 522 527.
15. Yu ML, Dai CY, Huang JF et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007 56 : 553 559.
16. Shiffman ML, Suter F, Bacon BR et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007 357 : 124 134.
17. Dalgard O, Bjoro K, Ring-Larsen H et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008 47 : 35 42.
18. Lagging M, Langeland N, Pedersen C et al. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008 47 : 1837 1845.
19. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Sheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994 19 : 1513 1520.
20. Izumi N, Asahina Y, Kurosaki M et al. A comparison of the exponential decay slope between PEG-IFN alfa-2b/ribavirin and IFN alfa-2b/ribavirin combination therapy in patients with chronic hepatitis C genotype 1b infection and a high viral load. Intervirology 2004 47 : 102 107.
21. Buti M, Sanchez-Avila F, Lurie Y et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology 2002 35 : 930 936.
22. Glue P, Rouzier-Panis R, Raffanel C et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. Hepatology 2000 32 : 647 653.
23. Asahina Y, Izumi N, Umeda N et al. Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin. J Viral Hepat 2007 14 : 396 403.